Understanding how short-term treatment can lead to long-term psoriasis remission
A clinical trial for psoriasis with novel single-cell genomic techniques to understand regulatory immunity behind long-term disease remission off drug induced by short-term IL-23 inhibition
This study is looking at how a short-term treatment with a specific medication can help people with psoriasis stay clear of their symptoms for a long time, by understanding how their immune system works in the skin.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10895963 on NIH RePORTER |
What this research studies
This research investigates how a short-term treatment with an IL-23 inhibitor can lead to long-term remission of psoriasis by examining the immune responses in patients. It aims to identify specific immune cell interactions that occur in the skin of patients who achieve lasting clearance of their psoriasis. By analyzing single-cell genomic data from skin biopsies, the study seeks to develop predictive models that can help anticipate which patients are likely to experience disease recurrence after treatment. This approach could provide insights into personalized treatment strategies for psoriasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are psoriasis patients who are receiving short-term IL-23 inhibitor treatment and are interested in understanding their immune response.
Not a fit: Patients with psoriasis who are not receiving IL-23 inhibitor treatment or those with other underlying conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for achieving long-term remission of psoriasis without the need for continuous medication.
How similar studies have performed: Other research has shown promise in using immune modulation strategies for chronic inflammatory diseases, suggesting potential success for this novel approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Kim, Jaehwan — University of California at Davis
- Study coordinator: Kim, Jaehwan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.